Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTHLH
REST API REST API
Homo sapiens
PTHLH is differentially expressed in 267 experiments: 97 organism parts: liver, lung, ... (95 more);, 123 disease states: normal, glioblastoma, ... (121 more);, 83 cell types 371 cell lines 28 compound treatments and 66 other conditions.
Synonyms PLP, PTHR, PTHRP, HHM
Orthologs Pthlh (Mus musculus)   PTHLH (2 of 3) (Danio rerio)   PTHLH (3 of 3) (Danio rerio)   PTHR_BOVIN (Bos taurus)   PTHLH (Gallus gallus)   pthlh (Danio rerio)   PTHR_RAT (Rattus norvegicus)   pthlh (Xenopus laevis)   PTHR_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoplasm, intracellular, negative regulation of cell proliferation, extracellular space, positive regulation of cell proliferation, extracellular region, cell-cell signaling, endoderm development, hormone activity, nucleus, protein processing, epidermis development, activation of adenylate cyclase activity by G-protein signaling pathway, regulation of gene expression, cAMP metabolic process, female pregnancy, positive regulation of cAMP biosynthetic process, endochondral ossification, nipple sheath formation, mammary gland bud elongation, lung alveolus development, osteoblast development, surfactant homeostasis, skeletal system development, negative regulation of chondrocyte differentiation, peptide hormone receptor binding, epithelial cell differentiation, negative regulation of sequence-specific DNA binding transcription factor activity
InterPro Term Parathyrd_hrm
UniProt Accession Q53XY9, P12272, Q15252, F5GZD9, F5H485
Gene-Disease Assocation BRACHYDACTYLY, TYPE E2; BDE2
Search EB-eye ENSG00000087494
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
HepG2
3
E-GEOD-7307, E-GEOD-21154, E-MTAB-37
PC3
3
E-GEOD-5258, E-GEOD-14464, E-MEXP-2034
A673
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MTAB-62, E-MEXP-440
A549
2
E-GEOD-3202, E-GEOD-6013
MOLT4
2
E-MTAB-37, E-MTAB-62
365 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-19397, E-GEOD-3920, E-GEOD-4219, ... (42 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
3
E-MTAB-24, E-AFMX-5, E-MTAB-25, E-TABM-145
memory B cell
2
E-MEXP-2360, E-TABM-702
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD8+ T cell
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
fibroblast
1
2
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
77 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-3678, E-GEOD-5370, E-MTAB-680, ... (49 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-6014
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
lung adenocarcinoma
2
E-MTAB-37, E-GEOD-2514
head and neck squamous cell carcinoma
1
2
E-MTAB-62, E-GEOD-6631, E-GEOD-2379
117 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, E-GEOD-6462, ... (19 experiments)

Factor Value U/D Experiments
unknown
1
E-GEOD-7307
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
NaOH
1
1
E-MEXP-2590
actinomycin D
1
E-GEOD-6400
valproic acid
1
E-GEOD-1615
TGF
1
1
E-GEOD-15205
22 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
40
2
1
E-GEOD-21653
81 years
1
1
E-GEOD-4922
81
1
1
E-GEOD-3494
90
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-TABM-783

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-TABM-440, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-9723, E-GEOD-2077, E-GEOD-6927, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-21750, E-GEOD-17636, E-GEOD-2487

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-1343, E-GEOD-20037

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-TABM-147

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Tumor size
studied in E-GEOD-3494

Processing time: 0.434 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM